Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Tight liquidity NBB
Cash and receivables cover 48 % of short-term debt in 2025; threshold 65 %.
Financials
Financial year 2025
ABAXYS THERAPEUTICS from Villers-la-Ville, company number BE0644674965, closed financial year 2025 with a result of € 75,495 after tax. For that financial year ABAXYS THERAPEUTICS recorded a gross margin of € 91,329 and equity of € 1 million. Compared with financial year 2024, the result moved from € -15,915 to € 75,495. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on August 17, 2026.
€ 1 million
▲ 74% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 75,495
▲ still € 15,915 loss in 2024
Profit after tax over the fiscal year.
€ 124,807
▲ € 103,182 vs 2024
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € -48,816.
Debts at end 2025
€ 150,000
▼ 24% vs 2024
Loans from banks and other lenders, long and short.
€ 105,146
▼ 75% vs 2024
Supplier invoices still open on the last day of the fiscal year.
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 2,543 | € -7,554 | € -5,463 | € 91,329 | ▲ € 96,792 |
| Profit after taxes | € -2,135 | € -19,605 | € -15,915 | € 75,495 | ▲ € 91,410 |
| Equity | € 362,631 | € 544,689 | € 598,151 | € 1,043,150 | ▲ 74% |
| Total debts | € 468,674 | € 540,770 | € 630,810 | € 264,542 | ▼ 58% |
| Cash | € 281,701 | € 24,383 | € 21,625 | € 124,807 | ▲ € 103,182 |
| Retained profit | € -88,790 | € -108,396 | € -124,311 | € -48,816 | ▲ € 75,495 |
| Bank debt | € 150,000 | € 150,000 | € 196,410 | € 150,000 | ▼ 24% |
| Balance sheet total | € 831,305 | € 1,085,459 | € 1,228,961 | € 1,307,692 | ▲ 6% |
Key figures of ABAXYS THERAPEUTICS, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to ABAXYS THERAPEUTICS?
What happened at ABAXYS THERAPEUTICS in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 75,495. filed late Source: NBB ↗
- Danielle Houart became a director. NBB
- Guillaume de Viron became a director. NBB
- Francisco Garcia Ladona became a director. NBB
- New establishment in Villers-la-Ville. KBO
- Start of the company according to the CBE. KBO
In short
From € 2,135 loss in 2022 to € 75,495 profit in 2025.
Best year ever: 2025, with € 75,495 profit.
Management
Behind ABAXYS THERAPEUTICS are Guillaume de Viron, Danielle Houart and Francisco Garcia Ladona. Francisco Garcia Ladona is also behind COMAXYS.
Directors
According to the 2025 annual accounts
Guillaume de Viron
Director
since 2018
Danielle Houart
Director
since 2022
since 2018
Establishments
Establishment units
Physical locations of this company
Rue du Berceau 91
1495 Villers-la-Ville
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0644.674.965
- VAT number
- BE 0644.674.965
- Registered office
- Rue du Berceau 91, 1495 Villers-la-Ville
- Names & denominations
- ABAXYS THERAPEUTICS
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 18 December 2015
- Peppol
- Active · Active since 11 Jun 2026
- Activities · NACE
Speur- en ontwikkelingswerk op biotechnologisch gebied
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied